RecruitingNCT06068361

Diagnostic Evaluation of Dementia with Lewy Bodies Using a Multimodal Approach

Diagnostic Evaluation of Dementia with Lewy Bodies Using a Multimodal Approach: EEG, Cognitive, Biological and MRI Biomarkers

Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

130 participants

Start Date

Sep 11, 2024

Study Type

OBSERVATIONAL

Conditions

Cognitive Impairment Alzheimer Disease Lewy Bodies Disease

Summary

Dementia with Lewy body disease (DLB) is the second leading cause of degenerative cognitive disorder after Alzheimer's disease (AD). Its variable clinical expression makes diagnosis difficult. To date, there is no validated DLB diagnostic biomarker, despite several biomarkers in development (EEG, MRI, biology). Studies have shown that an improvement in diagnostic performance could be obtained by combining different modalities biomarkers using machine learning. The aim of this research is to identify the best combination of multimodal biomarkers for the diagnosis of DLB (EEG, MRI, biology, cognitive scores), using a machine learning approach applied to a clinical cohort.

Eligibility

Min Age: 55 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study uses multiple tests together — brain scans, spinal fluid analysis, and specialized cognitive assessments — to better diagnose and differentiate dementia with Lewy bodies (DLB) from Alzheimer's disease (AD). Both conditions cause memory problems but have different causes and treatments. **You may be eligible if...** - You have been diagnosed with dementia with Lewy bodies (DLB) based on the 2017 McKeith criteria, OR with Alzheimer's disease (confirmed by CSF biomarkers) - Alternatively, if you are a control participant: you have no cognitive concerns - You can complete neuropsychological testing (good French language ability, no significant vision or hearing impairment) **You may NOT be eligible if...** - You have significant vision or hearing problems that prevent cognitive testing - You do not meet the diagnostic criteria for DLB or AD - You are a control patient but have cognitive complaints Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTEEG

32-electrode EEG (resting state, passive auditory and active visual task) + simultaneous recording with a 4 dry electrode EEG cap

Locations(1)

Centre de neurologie Cognitive

Paris, France, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06068361

Related Trials

Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease

NCT028116531 location

Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease

NCT072213443 locations

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787289 locations

Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.

NCT067813331 location

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

NCT07011745140 locations